JP2018537486A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537486A5
JP2018537486A5 JP2018530880A JP2018530880A JP2018537486A5 JP 2018537486 A5 JP2018537486 A5 JP 2018537486A5 JP 2018530880 A JP2018530880 A JP 2018530880A JP 2018530880 A JP2018530880 A JP 2018530880A JP 2018537486 A5 JP2018537486 A5 JP 2018537486A5
Authority
JP
Japan
Prior art keywords
cancer
diffraction pattern
ray powder
powder diffraction
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018530880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/065443 external-priority patent/WO2017105382A1/en
Publication of JP2018537486A publication Critical patent/JP2018537486A/ja
Publication of JP2018537486A5 publication Critical patent/JP2018537486A5/ja
Withdrawn legal-status Critical Current

Links

JP2018530880A 2015-12-14 2015-12-14 キノロン類似体及びその塩の結晶形 Withdrawn JP2018537486A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/065443 WO2017105382A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020144658A Division JP2020189888A (ja) 2020-08-28 2020-08-28 キノロン類似体及びその塩の結晶形

Publications (2)

Publication Number Publication Date
JP2018537486A JP2018537486A (ja) 2018-12-20
JP2018537486A5 true JP2018537486A5 (cg-RX-API-DMAC7.html) 2019-02-07

Family

ID=59057173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018530880A Withdrawn JP2018537486A (ja) 2015-12-14 2015-12-14 キノロン類似体及びその塩の結晶形

Country Status (10)

Country Link
EP (2) EP4249072A3 (cg-RX-API-DMAC7.html)
JP (1) JP2018537486A (cg-RX-API-DMAC7.html)
KR (1) KR20180111797A (cg-RX-API-DMAC7.html)
CN (1) CN108699083A (cg-RX-API-DMAC7.html)
AU (2) AU2015417382A1 (cg-RX-API-DMAC7.html)
CA (2) CA3006502A1 (cg-RX-API-DMAC7.html)
ES (1) ES2959536T3 (cg-RX-API-DMAC7.html)
IL (1) IL260004A (cg-RX-API-DMAC7.html)
RU (1) RU2018124599A (cg-RX-API-DMAC7.html)
WO (1) WO2017105382A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
EP3752149A4 (en) * 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
US12378245B2 (en) * 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
US20210046071A1 (en) * 2019-08-14 2021-02-18 Senhwa Biosciences, Inc. Tetracyclic compounds and their salts, compositions, and methods for their use
WO2021030686A1 (en) * 2019-08-14 2021-02-18 Senhwa Biosciences, Inc. Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
CN118005653B (zh) * 2023-04-23 2024-12-10 信义核新(北京)生物科技有限公司 喹诺酮类似物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553746A (en) * 2004-09-17 2010-06-25 Cylene Pharmaceuticals Inc Quinolone analogs as cell proliferation inhibitors
EP1926372A2 (en) * 2005-08-19 2008-06-04 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
KR101601332B1 (ko) 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
WO2012123938A1 (en) * 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
EP3074391B1 (en) * 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
WO2010115836A4 (en) Substituted piperidines as ccr3 antagonists
RU2018124599A (ru) Кристаллические формы аналогов хинолона и их солей
US20140309183A1 (en) Low-Dose Combination Chemotherapy
US10654876B2 (en) TH-302 solid forms and methods related thereto
JP2019514863A5 (cg-RX-API-DMAC7.html)
JP2020514271A5 (cg-RX-API-DMAC7.html)
US10472349B2 (en) Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof
US20160326138A1 (en) Process for preparing an anti-cancer agent, 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
RU2014151565A (ru) Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида
JP2021524835A5 (cg-RX-API-DMAC7.html)
JP2013538196A5 (cg-RX-API-DMAC7.html)
US20180110780A1 (en) Agent for alleviating side effect of antitumor drug
JP2019528276A5 (cg-RX-API-DMAC7.html)
JP2010505961A5 (cg-RX-API-DMAC7.html)
JP2012504590A5 (cg-RX-API-DMAC7.html)
RU2015111259A (ru) Способы проведения терапии пирфенидоном
HK1211289A1 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2016522835A5 (cg-RX-API-DMAC7.html)
TW200927113A (en) Qninoline derivatives for modulating DNA methylation
BRPI0916694B1 (pt) uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
US20110184032A1 (en) Novel Phenylamino Isonicotinamide Compounds
WO2019001425A1 (zh) 一种氘代奥斯替尼衍生物及其应用
US10654792B2 (en) Carboxylic acid ester prodrug inhibitors of MEK
WO2014007217A1 (ja) イミダゾオキサジン化合物による抗腫瘍効果増強剤
JP2019516749A5 (cg-RX-API-DMAC7.html)